The succinylation of p53 inhibits its function and transcriptional activity, which subsequently results in the suppression of p53 target gene expression
Glutathione is a main fuel source for immune cells, aiding in their proliferation and activation
Semaglutide and Cardiovascular Outcomes in Patients with Overweight or Obesity (SELECT) Trial : This trial specifically focused on the cardiovascular effects of semaglutide in individuals with obesity
The compound remains in Phase 3 clinical trials, with multiple studies expected to report results throughout this year
DSIP is an investigational peptide
Heart Diseases Hypertension Heart failure Cardiomyopathy Cardiac arrhythmias such as atrial fibrillation/flutter Endocrine Disorders Hypothyroid Hyperthyroid Parathyroid disorder Adrenal insufficiency Kidney Diseases Acute kidney failure Chronic kidney failure Electrolyte abnormalities Hypertension Lung Diseases Chronic obstructive pulmonary disease/emphysema Asthma Pulmonary fibrosis Reactive airway disease Pneumonias, and bronchitis Gastrointestinal Diseases Ulcerative colitis Crohn disease Irritable bowel syndrome Diarrhea Constipation Neurological Diseases Strokes Seizure disorders Movement disorders Neuropathies Post-stroke complications How GLP-1 Medications Work Semaglutide and Tirzepatide mimic natural hormones to regulate appetite, blood sugar, and metabolism creating the conditions for sustainable weight loss
